超声引导经皮不可逆电穿孔治疗手术切除后局部复发性胰腺癌。
Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection.
机构信息
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
出版信息
Anticancer Res. 2020 May;40(5):2771-2775. doi: 10.21873/anticanres.14249.
BACKGROUND/AIM: Irreversible electroporation (IRE) has recently been used as an experimental treatment for cancers including locally advanced pancreatic cancer. There is very limited data on IRE in pancreatic cancer that is locally recurrent after surgical resection. The aim of this study was to evaluate the safety and efficacy of IRE in this setting.
PATIENTS AND METHODS
Ten patients with locally recurrent pancreatic cancer without distant metastases after surgical resection were included and treated with ultrasound-guided percutaneous IRE.
RESULTS
Two patients had severe complications, of whom one died. Median disease-free survival was 3.3 months and overall median survival after IRE and resection was 16.5 and 42.7 months, respectively. Two patients are alive 42.1 and 23.9 months after the IRE without signs of local recurrence.
CONCLUSION
Percutaneous IRE in locally recurrent pancreatic cancer following curative resection is feasible, but should be regarded as a high-risk procedure that, at present, cannot be recommended outside of clinical trials. Further research is needed to select patients who might benefit from this treatment.
背景/目的：不可逆电穿孔（IRE）最近已被用作包括局部晚期胰腺癌在内的癌症的实验性治疗方法。在手术切除后局部复发的胰腺癌中，关于 IRE 的数据非常有限。本研究的目的是评估在这种情况下 IRE 的安全性和有效性。
患者和方法
纳入了 10 名手术切除后局部复发且无远处转移的局部晚期胰腺癌患者，并采用超声引导经皮 IRE 治疗。
结果
两名患者出现严重并发症，其中一名死亡。无病生存期中位数为 3.3 个月，IRE 后和切除后的总中位生存期分别为 16.5 个月和 42.7 个月。两名患者在 IRE 后 42.1 个月和 23.9 个月时无局部复发迹象，仍存活。
结论
根治性切除术后局部复发的胰腺癌患者行经皮 IRE 是可行的，但应将其视为一种高风险的手术，目前不能在临床试验之外推荐。需要进一步研究以选择可能受益于这种治疗的患者。
Zotero 插件